Search Results
Jun 26, 2026, 10:30 ET Epigenetics Market worth $3.92 billion by 2031 | MarketsandMarkets™
increasingly rely on NGS-based workflows for large-scale epigenetic profiling and multi-omics integration. The growing demand for liquid biopsy-based methylation biomarkers, single-cell epigenomics, and advanced cancer diagnostics further supports the leading position of the NGS segment in the epigenetics
More news about: MarketsandMarkets
Jun 25, 2026, 08:30 ET ePlus Expands Managed Services Portfolio with Enhanced Maintenance Support for HPE ProLiant Servers
HERNDON, Va., June 25, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 23, 2026, 08:30 ET ePlus Successfully Earns Place on CRN Solution Provider 500 List for 15 Consecutive Years
HERNDON, Va., June 23, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 22, 2026, 08:30 ET ePlus Honored with North America Networking Partner of the Year Award from HPE
HERNDON, Va., June 22, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 22, 2026, 07:00 ET Taiwan Biotech Delegation Heads to BIO 2026 to Advance Global Partnerships and Innovation
Instant NanoBiosensors (INB) provides protein biomarker platforms and integrated NGS solutions.Small Molecule
More news about: BPIPO
Jun 18, 2026, 07:07 ET Six Taipei Biotechs Head to BIO 2026 in San Diego, With Precision Medicine, Drug Delivery, and Bioprocess Innovation in Focus
platforms. Its biosensor technologies, FOPPR and FONLISA, are designed for highly sensitive detection of protein biomarkers. Separately, the INVISION INLab NGS Solution provides an integrated sample-to-report workflow combining automated instrumentation, proprietary reagents, and bioinformatics reporting systems
More news about: GeneOnline
Jun 17, 2026, 10:15 ET Transplant Diagnostics Market worth $8.14 billion by 2031 | MarketsandMarkets™
transplant diagnostic technologies, especially in emerging healthcare markets.Technological advancements, such as next-generation sequencing (NGS), real-time PCR, and other molecular assay techniques, have significantly improved the speed, accuracy, and sensitivity of transplant diagnostic procedures.A
More news about: MarketsandMarkets
Jun 17, 2026, 08:30 ET ePlus Receives Dell Technologies North America Strategic Impact Partner of the Year Award
HERNDON, Va., June 17, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 16, 2026, 10:01 ET PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand
platforms that support personalized immunotherapy decisions. Advances in immunohistochemistry (IHC), PCR-based diagnostics, and next-generation sequencing (NGS) are enabling faster and more accurate assessment of PD-L1 expression levels.PD-L1 assays are becoming critical for selecting patients eligible
More news about: Future Market Insights
Jun 16, 2026, 08:30 ET ePlus Named Digital Realty Americas Partner of the Year in Recognition of AI Expertise
ComplexityHERNDON, Va, June 16, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 15, 2026, 10:15 ET Companion Diagnostics Market worth $11.57 billion by 2031 | MarketsandMarkets™
therapies, particularly in oncology, autoimmune diseases, and rare genetic disorders. The market encompasses diagnostic assays, next-generation sequencing (NGS), PCR-based testing, immunohistochemistry, in situ hybridization, liquid biopsy technologies, bioinformatics platforms, and associated analytical services.
More news about: MarketsandMarkets
Jun 13, 2026, 11:40 ET MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations
PartnershipA key highlight of ESHG 2026 is the launch of the MGI NGS Partner Enablement Program, a new initiative designed to connect diagnostic developers, assay providers and laboratory partners seeking to build
More news about: MGI Tech Co., Ltd.
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
response rate (ORR), complete response or better (≥CR), and minimal residual disease (MRD)-negative ≥CR (10-5, next-generation sequencing [NGS]) for Tal-DP and Tal-D. ORRs (88.2%, 88.5%, 77.6%), ≥CR rates (71.1%, 68.9%, 34.5%) and MRD-negative ≥CR rates (52.3%, 46.3%, 15.9%) were significantly
More news about: Johnson & Johnson
Jun 12, 2026, 14:05 ET Volta Labs erweitert das Twist-Hybrid-Capture-Portfolio für Callisto™ mit der Einführung von Twist Fast Hyb
Volta Labs, ein Unternehmen für Genomik-Anwendungen, das die Probenvorbereitung für das Next-Generation-Sequencing (NGS) durch Automatisierung revolutioniert, gab heute die Einführung der App für das „Fast Hybridization Kit" von Twist Bioscience auf dem Callisto™-System
More news about: Volta Labs
Jun 12, 2026, 14:01 ET Volta Labs trae la cartera completa de captura híbrida Twist a Callisto™ con el lanzamiento de Twist Fast Hyb
Volta Labs, la empresa de aplicaciones genómicas que está transformando la preparación de muestras para la secuenciación de próxima generación (NGS) mediante la automatización, anunció hoy el lanzamiento de la aplicación para el kit de hibridación rápida de Twist Bioscience en el sistema de preparación
More news about: Volta Labs
Jun 12, 2026, 09:05 ET Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb
Volta Labs, the genomics applications company transforming next-generation sequencing (NGS) sample preparation through automation, today announced the launch of the App for Twist Bioscience's Fast Hybridization Kit on the Callisto™ Sample Prep
More news about: Volta Labs
Jun 12, 2026, 04:05 ET Volta Labs Brings the Complete Twist Hybrid Capture Portfolio to Callisto™ with Launch of Twist Fast Hyb
Volta Labs, the genomics applications company transforming next-generation sequencing (NGS) sample preparation through automation, today announced the launch of the App for Twist Bioscience's Fast Hybridization Kit on the Callisto™ Sample Prep
More news about: Volta Labs
Jun 11, 2026, 17:15 ET ChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted Therapeutics
Ancestry.com leading population genetics algorithm development and FDA 510(k) statistical submissions, and a directorship at Ambys Medicines overseeing NGS pipeline development in the gene and cell therapy space. Banda brings a rare combination of statistical rigor, computational depth, and translational
More news about: ChronicleBio
Jun 11, 2026, 08:26 ET Quintara Biosciences Relocates Boston Lab to Strengthen Service Capacity and Operational Readiness
zoning across laboratory, administrative, and collaboration areas. More defined operating space for key service lines, including Sanger sequencing, NGS, Nanopore sequencing, and DNA preparation, supports more organized sample intake, clearer team handoff, improved storage and resource planning, and stronger
More news about: Quintara Biosciences
Jun 08, 2026, 09:15 ET Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
more than 2000 samples per year.Speed: Multiple slides can be run in parallel, with library preparation and sequencing following traditional NGS methods. Sequencing takes as few as 22 hours. Including imaging, sequencing, and analysis, customers can move from sample to insight in less than 5 days.Accessibility:
More news about: Illumina, Inc.
Jun 05, 2026, 17:01 ET Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research
the forecast period is driven by technological innovations such as fast and accurate detection methods such as PCR & next-generation sequencing (NGS).Procure Complete Report (200 Pages PDF with Insights, Charts, Tables, and Figures) @
More news about: Allied Market Research
Jun 04, 2026, 08:00 ET SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center
used to analyze more than 2.5 million cases since 2014, pioneering a unique, decentralized approach to precision oncology. MSK's in-house NGS program has sequenced more than 150,000 tumor samples since 2014, creating an extensive genomic dataset linked to clinical outcomes, pathology, and radiology
More news about: SOPHiA GENETICS
Jun 03, 2026, 11:39 ET Point of Care Testing Market Poised for US$ 64.8 Bn Valuation by 2031, Growing at 7.5% CAGR, New Report by Wissen Research
these same products were added to the POC Testing categories. For example, the rapid growth of multiplex (PCR) systems and Next Generation Sequencing (NGS) technologies contributed to this segment's growth. Also, products like the BioFire® FilmArray® from bioMérieux, which expanded their manufacturing operations
More news about: Wissen Research LLC
Jun 03, 2026, 08:30 ET ePlus Demonstrates Enterprise-Grade Agentic AI Platform for Autonomous IT and Security Operations at Cisco Live
SolutionHERNDON, Va., June 3, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS) (news) today announced that it
More news about: EPLUS INC.
Jun 02, 2026, 16:05 ET Palo Alto Networks Reports Fiscal Third Quarter 2026 Financial Results
Chronosphere.Next-Generation Security ARR for the fiscal third quarter 2026 grew 60% year over year to $8.1 billion. This includes $1.6 billion in NGS ARR from CyberArk and Chronosphere.Remaining performance obligation grew 36% year over year to $18.4 billion. This includes $1.8 billion from
More news about: Palo Alto Networks, Inc.